|
1) |
Whitmore WF Jr. Natural history and staging of prostate cancer. Urol Clin North Am. 1984;11:205-20. |
2) |
Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology. 1991;37:418-22. |
3) |
Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195-202. |
4) |
Rana A, Karamanis K, Lucas MG, et al. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol. 1992;69:277-81. |
5) |
Oesterling JE. Prostate specific antigen:a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-23. |
6) |
Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer:prostate specific antigen is superior to all other clinical parameters. J Urol. 1991;145:313-8. |
7) |
Wolff JM, Bares R, Jung PK, et al. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int. 1996;56:169-73. |